In last trading session, C4 Therapeutics Inc (NASDAQ:CCCC) saw 1.25 million shares changing hands with its beta currently measuring 2.96. Company’s recent per share price level of $3.01 trading at $0.04 or 1.35% at ring of the bell on the day assigns it a market valuation of $212.47M. That closing price of CCCC’s stock is at a discount of -294.68% from its 52-week high price of $11.88 and is indicating a premium of 1.33% from its 52-week low price of $2.97.

For C4 Therapeutics Inc (CCCC), analysts’ consensus is at an average recommendation of Hold while assigning it a mean rating of 1.80. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.45 in the current quarter.

C4 Therapeutics Inc (NASDAQ:CCCC) trade information

Upright in the green during last session for gaining 1.35%, in the last five days CCCC remained trading in the red while hitting it’s week-highest on Thursday, 02/13/25 when the stock touched $3.01 price level, adding 10.95% to its value on the day. C4 Therapeutics Inc’s shares saw a change of -16.39% in year-to-date performance and have moved -7.95% in past 5-day. C4 Therapeutics Inc (NASDAQ:CCCC) showed a performance of -23.60% in past 30-days.

Wall Street analysts have assigned a consensus price target of 16 to the stock, which implies a rise of 81.19% to its current value. Analysts have been projecting 12 as a low price target for the stock while placing it at a high target of 20. It follows that stock’s current price would drop -298.67% in reaching the projected high whereas dropping to the targeted low would mean a loss of -298.67% for stock’s current value.

C4 Therapeutics Inc (CCCC) estimates and forecasts

This year revenue growth is estimated to rise 72.35% from the last financial year’s standing.

7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 4.43M for the same. And 3 analysts are in estimates of company making revenue of 3.33M in the next quarter. Company posted 3.26M and 3.04M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -36.05% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 44.17% while estimates for its earnings growth in next 5 years are of 12.86%.

C4 Therapeutics Inc (NASDAQ:CCCC)’s Major holders

LYNX1 CAPITAL MANAGEMENT LP is the top institutional holder at CCCC for having 6.88 million shares of worth $31.79 million. And as of 2024-06-30, it was holding 9.9993 of the company’s outstanding shares.

The second largest institutional holder is RA CAPITAL MANAGEMENT, L.P., which was holding about 4.88 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.0891 of outstanding shares, having a total worth of $22.54 million.

On the other hand, Wasatch Ultra Growth Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 3.38 shares of worth $10.18 million or 4.79% of the total outstanding shares. The later fund manager was in possession of 2.14 shares on Sep 30, 2024 , making its stake of worth around $6.43 million in the company or a holder of 3.03% of company’s stock.